ALXN News and Press, Alexion Pharmaceuticals Inc. From 10/16/19

Alexion Pharmaceuticals (NASDAQ: ALXN ) has agreed to acquire Achillion Pharmaceuticals (NASDAQ: ACHN ) for $6.30 per share in cash for a total of ~$930M, including Achillion's cash on hand of ~$230M. More news on: Alexion Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., Healthcar...

- Adds clinical-stage portfolio of oral small molecule Factor D inhibitors to Alexion’s pipeline - - Provides opportunity to enhance treatment for PNH patients experiencing extravascular hemolysis (EVH), potential first-in-class C3 glomerulopathy (C3G) therapy & promising de...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to...

On the good news front in today's series, Stealth BioTherapeutics ( MITO ) and Alexion Pharmaceuticals ( ALXN ) have agreed to co-develop and commercialize elamipretide for mitochondrial diseases. Elamipretide, an inner mitochondrial membrane-targeting therapeutic, is Stealth BioTherapeutics...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Biotech is in the doldrums. The SPDR S&P Biotech ETF  declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...

- Dr. Carino to head up newly integrated Corporate Affairs function including global government affairs, public policy and communications - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of Tanisha Carino, Ph.D., as Executive Vice President and the comp...

Alexion Pharmaceuticals (NASDAQ: ALXN ) inks an agreement with Stealth BioTherapeutics (NASDAQ: MITO ) securing an option to co-develop and commercialize elamipretide for mitochondrial diseases. More news on: Alexion Pharmaceuticals, Inc., Stealth BioTherapeutics Corp, Healthcare stocks ...

- Elamipretide in Phase 3 development for primary mitochondrial myopathy - - If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive exclusive ex-U.S. license - - Stealth to receive initial payment o...

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2019 before the US financial markets open on October 23, 2019. Following the release of the financial results, Alexion management will conduct a c...